Molbio Diagnostics IPO
Molbio Diagnostics IPO Details
-
उघडण्याची तारीख
10 ऑगस्ट 2026
-
बंद तारीख
12 ऑगस्ट 2026
- IPO प्राईस रेंज
₹768 ते ₹807
- IPO साईझ
₹ 939.70 कोटी
Molbio Diagnostics IPO Timeline
Molbio Diagnostics IPO Subscription Status
| तारीख | क्यूआयबी | एनआयआय | रिटेल | एकूण |
|---|---|---|---|---|
| 10-Aug-2026 | 1.00 | 0.73 | 0.77 | 0.83 |
| 11-Aug-2026 | 1.39 | 4.46 | 3.19 | 2.95 |
अंतिम अपडेट: 11 ऑगस्ट 2026 5:36 PM पर्यंत 5paisa
Molbio Diagnostics Limited is a global point-of-care molecular diagnostics company specialising in the development, manufacture and commercialisation of rapid diagnostic solutions. Its proprietary battery-operated Truenat PCR platform delivers accurate results within an hour, even in resource-constrained settings. The company offers diagnostic assays for more than 30 diseases, operates six manufacturing facilities in India, serves customers across 90+ countries, and continues to strengthen its portfolio through innovation, strategic collaborations and acquisitions.
स्थापित: 2000
Managing Director: Vajapeyam Krishna Prasad
Molbio Diagnostics Objectives
1. Funding capital expenditure towards the setting up of infrastructure for research and development facility, Center of Excellence and connected office space.
2. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
3. सामान्य कॉर्पोरेट उद्देश
Molbio Diagnostics IPO Size
| प्रकार | साईझ |
|---|---|
| एकूण IPO साईझ | ₹ 939.70 कोटी |
| विक्रीसाठी ऑफर | ₹ 739.70 कोटी |
| नवीन समस्या | ₹ 200.00 कोटी |
Molbio Diagnostics IPO Lot Size
| ॲप्लिकेशन | लॉट्स | शेअर्स | रक्कम (₹) |
|---|---|---|---|
| वैयक्तिक गुंतवणूकदार (आयएनडी) (किमान) | 1 | 18 | ₹13,824 |
| वैयक्तिक गुंतवणूकदार (आयएनडी) (कमाल) | 13 | 234 | ₹1,80,838 |
| S - HNI (मि) | 14 | 252 | ₹1,93,536 |
| S - HNI (कमाल) | 68 | 1,224 | ₹9,97,050 |
| B - HNI (किमान) | 69 | 1,242 | ₹9,53,856 |
Molbio Diagnostics IPO Reservation
| इन्व्हेस्टर्स कॅटेगरी | सबस्क्रिप्शन (वेळा) | ऑफर केलेले शेअर्स* | यासाठी शेअर्स बिड | एकूण रक्कम (कोटी)* |
|---|---|---|---|---|
| क्यूआयबी (एक्स अँकर) | 1.39 | 23,25,146 | 32,34,672 | 261.038 |
| गैर-संस्थात्मक खरेदीदार | 4.46 | 17,43,859 | 77,84,946 | 628.245 |
| बीएनआयआय | 4.31 | 11,62,573 | 50,08,518 | 404.187 |
| एसएनआयआय | 7.02 | 5,81,286 | 40,78,548 | 329.139 |
| वैयक्तिक गुंतवणूकदार (2 लॉट्ससाठी इंड कॅटेगरी बिडिंग) | 3.19 | 40,69,004 | 1,29,84,534 | 1,047.852 |
| एकूण** | 2.95 | 81,58,529 | 2,41,02,360 | 1,945.060 |
*"ऑफर केलेले शेअर्स" आणि "एकूण रक्कम" जारी किंमतीच्या श्रेणीच्या वरच्या मर्यादेचा वापर करून कॅल्क्युलेट केले जातात.
**अँकर इन्व्हेस्टरला (किंवा मार्केट मेकर्स) वाटप केलेले शेअर्स ऑफर केलेल्या एकूण शेअर्सच्या संख्येमधून वगळले जातात.
| तपशील (₹ कोटीमध्ये) | FY24 | FY25 | FY26 |
| महसूल | 836.56 | 1020.42 | 1445.69 |
| EBITDA | 185.09 | 256.64 | 328.24 |
| पॅट | 83.54 | 138.58 | 164.14 |
| तपशील (₹ कोटीमध्ये) | FY24 | FY25 | FY26 |
| एकूण मालमत्ता | 1221.06 | 1461.56 | 2148.24 |
| शेअर कॅपिटल | 2.25 | 2.26 | 11.28 |
| एकूण दायित्व | 392.22 | 494.27 | 839.652 |
| कॅश फ्लो (₹ कोटी) | FY24 | FY25 | FY26 |
| ऑपरेटिंग उपक्रमांमधून/(वापरलेले) निव्वळ कॅश निर्माण | 9.57 | 287.10 | 50.39 |
| गुंतवणूक उपक्रमांमधून/(वापरलेले) निव्वळ कॅश निर्माण | -45.01 | -122.65 | -93.22 |
| फायनान्सिंग उपक्रमांमधून/(वापरलेले) निव्वळ कॅश निर्माण | -31.55 | -26.15 | -276.07 |
| कॅश आणि कॅश समतुल्यांमध्ये निव्वळ वाढ (कमी) | 66.99 | 138.30 | 233.23 |
सामर्थ्य
1. Proprietary Truenat platform enables rapid, accurate molecular diagnostics.
2. Strong portfolio covering over 30 disease-specific diagnostic assays.
3. Extensive global presence across more than 90 countries.
4. Robust in-house research supports continuous product innovation.
कमकुवतता
1. Significant reliance on government healthcare procurement programmes.
2. Revenue vulnerable to fluctuating pandemic-related testing demand.
3. High research expenditure may pressure operating profitability.
4. Limited diversification beyond molecular diagnostics core business.
संधी
1. Rising demand for decentralised point-of-care diagnostic solutions.
2. Expansion into emerging markets with underserved healthcare infrastructure.
3. Growing non-communicable disease testing broadens addressable market opportunities.
4. Strategic acquisitions can strengthen technology and product portfolio.
धोके
1. Intense competition from established global diagnostics manufacturers.
2. Regulatory changes may delay product approvals and launches.
3. Pricing pressure from government tenders affects profit margins.
4. Rapid technological advancements could accelerate product obsolescence.
1. Proprietary Truenat platform offers strong competitive technological advantage.
2. Expanding global footprint supports long-term revenue growth potential.
3. Diversified disease portfolio reduces dependence on single diagnostics segment.
4. Strong innovation pipeline backed by sustained research investments.
The global molecular diagnostics market is expanding rapidly, driven by increasing demand for early disease detection, decentralised healthcare and technological advancements. In India, favourable government initiatives, rising healthcare expenditure and growing awareness of infectious and chronic diseases are supporting market growth. Point-of-care molecular diagnostics are expected to witness strong adoption, particularly in resource-limited settings, creating significant long-term opportunities for companies with innovative, scalable and cost-effective diagnostic platforms.
मोफत डिमॅट अकाउंट उघडा
5paisa कम्युनिटीचा भाग बना - भारताचे पहिले लिस्टेड डिस्काउंट ब्रोकर.
पुढे सुरू ठेवण्याद्वारे, तुम्ही सर्व अटी व शर्ती* मान्य करता
एफएक्यू
Molbio Diagnostics opens from August 10, 2025 to August 12, 2026.
The size of Molbio Diagnostics is ₹939.70 कोटी.
The price band of Molbio Diagnostics IPO is fixed at ₹768 to ₹807.
Once the Molbio Diagnostics IPO is officially open, one can simply follow the process to apply for the IPO:
To apply for Molbio Diagnostics IPO, follow the steps given below:
● तुमच्या 5paisa अकाउंटमध्ये लॉग-इन करा आणि वर्तमान IPO सेक्शनमध्ये समस्या निवडा
● Enter the number of lots and the price at which you wish to apply for the Molbio Diagnostics IPO
● तुमचा UPI ID प्रविष्ट करा आणि सबमिट करा वर क्लिक करा. यासह, तुमची बिड एक्सचेंजसह दिली जाईल
तुम्हाला तुमच्या UPI ॲपमध्ये फंड ब्लॉक करण्यासाठी मँडेट नोटिफिकेशन प्राप्त होईल.
The minimum lot size of Molbio Diagnostics is of 18 shares and the investment required is ₹13,824.
The share allotment date of Molbio Diagnostics IPO is August 13, 2026
The Molbio Diagnostics IPO will likely be listed on August 17, 2026.
Kotak Mahindra Capital Co.Ltd is the book running lead managers for Molbio Diagnostics IPO.
1. Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit, and
2. सामान्य कॉर्पोरेट उद्देश